Clinical trial NCT03723837 - References

Poliomyelitis — Persistence of IPV Immunity

Citation(s)

•   Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MA
  Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis. 2005 Mar 15;191(6):990-9. Epub 2005 Feb 10.
•   Anand A, Zaman K, Estívariz CF, Yunus M, Gary HE, Weldon WC, Bari TI, Steven Oberste M, Wassilak SG, Luby SP, Heffelfinger JD, Pallansch MA
  Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine. 2015 Nov 27;33(48):6816-22. doi: 10.1016/j.vaccine.2015.09.039. Epub 2015 Oct 23.
•   Asturias EJ, Bandyopadhyay AS, Self S, Rivera L, Saez-Llorens X, Lopez E, Melgar M, Gaensbauer JT, Weldon WC, Oberste MS, Borate BR, Gast C, Clemens R, Orenstein W, O'Ryan G M, Jimeno J, Clemens SA, Ward J, Rüttimann R; Latin American IPV001BMG Study Group
  Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016 Jul 9;388(10040):158-69. doi: 10.1016/S0140-6736(16)00703-0. Epub 2016 May 19. Erratum in: Lancet. 2016 Jul 9;388(10040):e2.
•   Burns CC, Diop OM, Sutter RW, Kew OM
  Vaccine-derived polioviruses. J Infect Dis. 2014 Nov 1;210 Suppl 1:S283-93. doi: 10.1093/infdis/jiu295. Review.
•   Carlsson RM, Claesson BA, Fagerlund E, Knutsson N, Lundin C
  Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J. 2002 Jun;21(6):535-41.
•   Dayan GH, Thorley M, Yamamura Y, Rodríguez N, McLaughlin S, Torres LM, Seda A, Carbia M, Alexander LN, Caceres V, Pallansch MA
  Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis. 2007 Jan 1;195(1):12-20. Epub 2006 Nov 28.
•   Dowdle WR, Cochi SL
  Global eradication of poliovirus: History and rationale. In: Semler BL, Wimmer E, eds. Molecular Biology of Picornaviruses. Washington: ASM Press, 2002:473-480
•   Estívariz CF, Anand A, Gary HE Jr, Rahman M, Islam J, Bari TI, Wassilak SG, Chu SY, Weldon WC, Pallansch MA, Heffelfinger JD, Luby SP, Zaman K
  Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial. Lancet Infect Dis. 2015 Aug;15(8):898-904. doi: 10.1016/S1473-3099(15)00094-8. Epub 2015 Jun 17.
•   Estívariz CF, Jafari H, Sutter RW, John TJ, Jain V, Agarwal A, Verma H, Pallansch MA, Singh AP, Guirguis S, Awale J, Burton A, Bahl S, Chatterjee A, Aylward RB
  Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis. 2012 Feb;12(2):128-35. doi: 10.1016/S1473-3099(11)70190-6. Epub 2011 Nov 7.
•   Estívariz CF, Pallansch MA, Anand A, Wassilak SG, Sutter RW, Wenger JD, Orenstein WA
  Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol. 2013 Jun;3(3):309-15. doi: 10.1016/j.coviro.2013.05.007. Epub 2013 Jun 10. Review.
•   Ghendon Y, Robertson SE
  Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ. 1994;72(6):973-83. Review.
•   Halperin SA, Smith B, Russell M, Scheifele D, Mills E, Hasselback P, Pim C, Meekison W, Parker R, Lavigne P, Barreto L
  Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J. 2000 Apr;19(4):276-83.
•   Kaml M, Weiskirchner I, Keller M, Luft T, Hoster E, Hasford J, Young L, Bartlett B, Neuner C, Fischer KH, Neuman B, Würzner R, Grubeck-Loebenstein B
  Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine. 2006 Nov 17;24(47-48):6808-11. Epub 2006 Jul 10.
•   Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA
  Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587-635. Review.
•   McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R
  Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol. 1988 Sep;128(3):615-28.
•   Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 – conclusions and recommendations
  Wkly Epidemiol Rec. 2013 Jan 4;88(1):1-16. English, French.
•   Mohammed AJ, AlAwaidy S, Bawikar S, Kurup PJ, Elamir E, Shaban MM, Sharif SM, van der Avoort HG, Pallansch MA, Malankar P, Burton A, Sreevatsava M, Sutter RW
  Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med. 2010 Jun 24;362(25):2351-9. doi: 10.1056/NEJMoa0909383.
•   Moriniere BJ, van Loon FP, Rhodes PH, Klein-Zabban ML, Frank-Senat B, Herrington JE, Pallansch MA, Patriarca PA
  Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet. 1993 Jun 19;341(8860):1545-50.
•   Nathanson N, Kew OM
  From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010 Dec 1;172(11):1213-29. doi: 10.1093/aje/kwq320. Epub 2010 Oct 26. Review.
•   O'Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, Clemens R, Orenstein W, Jimeno J, Rüttimann R, Costa Clemens SA; Chilean IPV/bOPV study group
  Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis. 2015 Nov;15(11):1273-82. doi: 10.1016/S1473-3099(15)00219-4. Epub 2015 Aug 26. Erratum in: Lancet Infect Dis. 2015 Oct;15(10):1130.
•   Ogra PL, Fishaut M, Gallagher MR
  Viral vaccination via the mucosal routes. Rev Infect Dis. 1980 May-Jun;2(3):352-69. Review.
•   Ogra PL, Okayasu H, Czerkinsky C, Sutter RW
  Mucosal immunity to poliovirus. Expert Rev Vaccines. 2011 Oct;10(10):1389-92. doi: 10.1586/erv.11.106.
•   Patriarca PA, Linkins RW and Sutter RW
  Poliovirus vaccine formulations. In: Kurstak E, ed. Measles and Poliomyelitis. Wiena: Springer-Verlag, 1993:267-277
•   Patriarca PA, Wright PF, John TJ
  Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991 Sep-Oct;13(5):926-39. Review.
•   Platt LR, Estívariz CF, Sutter RW
  Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014 Nov 1;210 Suppl 1:S380-9. doi: 10.1093/infdis/jiu184. Review.
•   Resik S, Tejeda A, Lago PM, Diaz M, Carmenates A, Sarmiento L, Alemañi N, Galindo B, Burton A, Friede M, Landaverde M, Sutter RW
  Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010 May 1;201(9):1344-52. doi: 10.1086/651611.
•   Resik S, Tejeda A, Sutter RW, Diaz M, Sarmiento L, Alemañi N, Garcia G, Fonseca M, Hung LH, Kahn AL, Burton A, Landaverde JM, Aylward RB
  Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med. 2013 Jan 31;368(5):416-24. doi: 10.1056/NEJMoa1202541.
•   Roivainen M, Thodén CJ, Stenvik M, Pöyry T, Hovi T
  Virus excretion and strain specific antibody responses after oral poliovaccine in previously immunised children. J Med Virol. 1987 Nov;23(3):249-56.
•   Rümke HC, Oostvogel PM, Van Steenis G, Van Loon AM
  Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Epidemiol Infect. 1995 Oct;115(2):289-98. Review.
•   Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, Rao JV, Agarkhedkar S, Lalwani SK, Kunwar A, Sethi R, Takane M, Mohanty L, Chatterjee A, John TJ, Jafari H, Aylward RB
  Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet. 2015 Dec 12;386(10011):2413-21. doi: 10.1016/S0140-6736(15)00237-8. Epub 2015 Sep 18. Erratum in: Lancet. 2015 Dec 12;386(10011):2394.
•   Sutter RW, Cochi SL and Melnick J
  Poliovirus vaccine - live. 2002
•   Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H, Deshpande J, Singh AP, Sreevatsava M, Malankar P, Burton A, Chatterjee A, Jafari H, Aylward RB
  Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010 Nov 13;376(9753):1682-8. doi: 10.1016/S0140-6736(10)61230-5. Epub 2010 Oct 25.
•   Sutter RW, Kew OM, Cochi SL and Aylward RB
  Poliovirus vaccine - live. In: Plotkin SA, Orenstein WA and Offit PA, eds. Vaccines. 6th ed: Elsevier, 2013:598-645
•   Sutter RW, Patriarca PA
  Inactivated and live, attenuated poliovirus vaccines: mucosal immunity. In: Kurstak E, ed. Measles and poliomyelitis. Austria: Springer-Verlag, 1993:279-293
•   Swartz TA, Handsher R, Stoeckel P, Drucker J, Caudrelier P, Van Wezel AL, Cohen H, Salk D, Salk J
  Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur J Epidemiol. 1989 Jun;5(2):143-5.
•   Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Sutter RW, Aylward RB, Thompson KM
  Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006 Dec;26(6):1471-505.
•   Thompson KM, Duintjer Tebbens RJ
  National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. Expert Rev Vaccines. 2014 Feb;13(2):221-34. doi: 10.1586/14760584.2014.864563. Epub 2013 Dec 4. Review.
•   Vidor E, Plotkin SA
  Poliovirus vaccine - Inactivated. In: Plotkin SA, Orenstein WA and Offit PA, eds. Vaccine. 6th ed. Philadelphia: Elsevier, 2013:573-597
•   Zimmermann U, Gavazzi G, Richard P, Eymin C, Soubeyrand B, Baudin M
  Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged =60 years: an open-label, randomised trial. Vaccine. 2013 Mar 1;31(11):1496-502. doi: 10.1016/j.vaccine.2012.12.081. Epub 2013 Jan 10.

Cross-sectional Study to Assess Persistence of Immunity Conferred by a Single IPV Dose Administered in the Expanded Program on Immunization(EPI) Routine Immunization Schedule

Details for clinical trial NCT03723837